The FDA has taken a clear position with Project Optimus in shifting toward more progressive tailored approaches while rejecting antiquated study designs to evolve clinical trial strategies to better align with newer drug classes.
Sirj Goswami, PhD, and Jason Rizzo, MBA
Advertisement
Articles by Sirj Goswami, PhD, and Jason Rizzo, MBA
Advertisement
Latest Updated Articles
Artificial Intelligence Drives Industry Response to Project OptimusPublished: February 27th 2024 | Updated:
Advertisement
Advertisement
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
